374 related articles for article (PubMed ID: 23777648)
1. The MAO inhibitor phenelzine can improve functional outcomes in mice with established clinical signs in experimental autoimmune encephalomyelitis (EAE).
Benson CA; Wong G; Tenorio G; Baker GB; Kerr BJ
Behav Brain Res; 2013 Sep; 252():302-11. PubMed ID: 23777648
[TBL] [Abstract][Full Text] [Related]
2. The MAO inhibitor phenelzine improves functional outcomes in mice with experimental autoimmune encephalomyelitis (EAE).
Musgrave T; Benson C; Wong G; Browne I; Tenorio G; Rauw G; Baker GB; Kerr BJ
Brain Behav Immun; 2011 Nov; 25(8):1677-88. PubMed ID: 21723939
[TBL] [Abstract][Full Text] [Related]
3. Changes in nociceptive sensitivity and object recognition in experimental autoimmune encephalomyelitis (EAE).
Olechowski CJ; Tenorio G; Sauve Y; Kerr BJ
Exp Neurol; 2013 Mar; 241():113-21. PubMed ID: 23291347
[TBL] [Abstract][Full Text] [Related]
4. Altered excitatory-inhibitory balance within somatosensory cortex is associated with enhanced plasticity and pain sensitivity in a mouse model of multiple sclerosis.
Potter LE; Paylor JW; Suh JS; Tenorio G; Caliaperumal J; Colbourne F; Baker G; Winship I; Kerr BJ
J Neuroinflammation; 2016 Jun; 13(1):142. PubMed ID: 27282914
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase 5 inhibition at disease onset prevents experimental autoimmune encephalomyelitis progression through immunoregulatory and neuroprotective actions.
Pifarré P; Gutierrez-Mecinas M; Prado J; Usero L; Roura-Mir C; Giralt M; Hidalgo J; García A
Exp Neurol; 2014 Jan; 251():58-71. PubMed ID: 24211383
[TBL] [Abstract][Full Text] [Related]
6. The blood-brain barrier-permeable catechol-O-methyltransferase inhibitor dinitrocatechol suppresses experimental autoimmune encephalomyelitis.
Polak PE; Lin SX; Pelligrino D; Feinstein DL
J Neuroimmunol; 2014 Nov; 276(1-2):135-41. PubMed ID: 25242632
[TBL] [Abstract][Full Text] [Related]
7. Chronic exercise confers neuroprotection in experimental autoimmune encephalomyelitis.
Pryor WM; Freeman KG; Larson RD; Edwards GL; White LJ
J Neurosci Res; 2015 May; 93(5):697-706. PubMed ID: 25510644
[TBL] [Abstract][Full Text] [Related]
8. Cytokine production profiles in chronic relapsing-remitting experimental autoimmune encephalomyelitis: IFN-γ and TNF-α are important participants in the first attack but not in the relapse.
Hidaka Y; Inaba Y; Matsuda K; Itoh M; Kaneyama T; Nakazawa Y; Koh CS; Ichikawa M
J Neurol Sci; 2014 May; 340(1-2):117-22. PubMed ID: 24655735
[TBL] [Abstract][Full Text] [Related]
9. Differential brain and spinal cord cytokine and BDNF levels in experimental autoimmune encephalomyelitis are modulated by prior and regular exercise.
Bernardes D; Oliveira-Lima OC; Silva TV; Faraco CC; Leite HR; Juliano MA; Santos DM; Bethea JR; Brambilla R; Orian JM; Arantes RM; Carvalho-Tavares J
J Neuroimmunol; 2013 Nov; 264(1-2):24-34. PubMed ID: 24054000
[TBL] [Abstract][Full Text] [Related]
10. RGS10 deficiency ameliorates the severity of disease in experimental autoimmune encephalomyelitis.
Lee JK; Kannarkat GT; Chung J; Joon Lee H; Graham KL; Tansey MG
J Neuroinflammation; 2016 Feb; 13():24. PubMed ID: 26831924
[TBL] [Abstract][Full Text] [Related]
11. Single β³-amino acid substitutions to MOG peptides suppress the development of experimental autoimmune encephalomyelitis.
McDonald CA; Payne NL; Sun G; Clayton DJ; Del Borgo MP; Aguilar MI; Perlmutter P; Bernard CC
J Neuroimmunol; 2014 Dec; 277(1-2):67-76. PubMed ID: 25454728
[TBL] [Abstract][Full Text] [Related]
12. 2-BFI ameliorates EAE-induced mouse spinal cord damage: effective therapeutic time window and possible mechanisms.
Li F; Zhang ZX; Liu YF; Xu HQ; Hou ST; Zheng RY
Brain Res; 2012 Nov; 1483():13-9. PubMed ID: 22985669
[TBL] [Abstract][Full Text] [Related]
13. Treatment of an autoimmune encephalomyelitis mouse model with nonmyeloablative conditioning and syngeneic bone marrow transplantation.
Meng L; Ouyang J; Zhang H; Wen Y; Chen J; Zhou J
Restor Neurol Neurosci; 2011; 29(3):177-85. PubMed ID: 21586824
[TBL] [Abstract][Full Text] [Related]
14. Primaquine treatment suppresses experimental autoimmune encephalomyelitis severity.
Zanucoli F; Thomé R; Bonfanti AP; de Carvalho AC; Issayama LK; da Costa TA; Di Gangi R; Ferreira IT; Bombeiro AL; de Oliveira AL; Verinaud L
CNS Neurosci Ther; 2014 Dec; 20(12):1061-4. PubMed ID: 25417930
[No Abstract] [Full Text] [Related]
15. Kinematic gait parameters are highly sensitive measures of motor deficits and spinal cord injury in mice subjected to experimental autoimmune encephalomyelitis.
Fiander MD; Stifani N; Nichols M; Akay T; Robertson GS
Behav Brain Res; 2017 Jan; 317():95-108. PubMed ID: 27639322
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulatory effects and improved prognosis of experimental autoimmune encephalomyelitis after O-tetradecanoyl-genistein treatment.
Castro SB; Junior CO; Alves CC; Dias AT; Alves LL; Mazzoccoli L; Mesquita FP; Figueiredo NS; Juliano MA; Castañon MC; Gameiro J; Almeida MV; Teixeira HC; Ferreira AP
Int Immunopharmacol; 2012 Feb; 12(2):465-70. PubMed ID: 22245971
[TBL] [Abstract][Full Text] [Related]
17. Decreased severity of experimental autoimmune encephalomyelitis during resveratrol administration is associated with increased IL-17+IL-10+ T cells, CD4(-) IFN-gamma+ cells, and decreased macrophage IL-6 expression.
Imler TJ; Petro TM
Int Immunopharmacol; 2009 Jan; 9(1):134-43. PubMed ID: 19022403
[TBL] [Abstract][Full Text] [Related]
18. Total glucosides of peony attenuates experimental autoimmune encephalomyelitis in C57BL/6 mice.
Huang Q; Ma X; Zhu DL; Chen L; Jiang Y; Zhou L; Cen L; Pi R; Chen X
J Neuroimmunol; 2015 Jul; 284():67-73. PubMed ID: 26025060
[TBL] [Abstract][Full Text] [Related]
19. An electrophysiologic approach to quantify impaired synaptic transmission and plasticity in experimental autoimmune encephalomyelitis.
Prochnow N; Gold R; Haghikia A
J Neuroimmunol; 2013 Nov; 264(1-2):48-53. PubMed ID: 24090654
[TBL] [Abstract][Full Text] [Related]
20. Voluntary wheel running differentially affects disease outcomes in male and female mice with experimental autoimmune encephalomyelitis.
Mifflin KA; Frieser E; Benson C; Baker G; Kerr BJ
J Neuroimmunol; 2017 Apr; 305():135-144. PubMed ID: 28284334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
